Table 4.
Significant gene associations with treatment resistant hypertension.
| Variant name | Rs number | Geno-type | African American | White | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| TRH cases | Controls | Odds ratio (95% CI)* | P value* | TRH cases | Controls | Odds ratio (95% CI)* | P value* | |||
| TT | 640 (70.6) | 463 (66.5) | 228 (18.2) | 380 (23.5) | ||||||
| AGTM235T | 699 | TM | 237 (26.1) | 203 (29.2) | 0.83 (0.67–1.03) | 0.10 | 597 (47.5) | 801 (49.6) | 1.27 (1.12–1.44) | 0.0001 |
| MM | 30 (3.3) | 30 (4.3) | 431 (34.3) | 434 (26.9) | ||||||
|
| ||||||||||
| AA | 658 (72.0) | 496 (69.9) | 226 (18.1) | 401 (24.7) | ||||||
| AGT-6G | 5051 | AG | 231 (25.3) | 187 (26.3) | 0.90 (0.72–1.12) | 0.35 | 597 (47.9) | 806 (49.7) | 1.36 (1.20–1.53) | <0.0001 |
| GG | 25 (2.7) | 27 (3.8) | 424 (34.0) | 414 (25.5) | ||||||
*Odds of being a case versus control for each copy of the minor allele (additive genetic model) after adjustment for age, sex, randomized treatment group, baseline values of BMI, HDL, eGFR, SBP, and DBP, smoking status, diabetes status, and history of LVH.